(±)-U-50488|CAS 83913-05-7|DC Chemicals

Cas No.:	83913-05-7
Chemical Name:	TRANS-(+/-)-3,4-DICHLORO-N-METHYL-N-(2-[1-PYRROLIDINYL]CYCLOHEXYL)-BENZENEACETAMIDE METHANESULFONATE SALT
Synonyms:	TRANS-(+/-)-3,4-DICHLORO-N-METHYL-N-(2-[1-PYRROLIDINYL]CYCLOHEXYL)-BENZENEACETAMIDE METHANESULFONATE SALT;TRANS-(+/-)-3,4-DICHLORO-N-METHYL-N-(2-[1-PYRROLIDINYL]CYCLOHEXYL)-BENZENEACETAMIDE METHANESUL...;U 50488H;CHEMBL482811;SCHEMBL548872;NCG-C00093883-01;Opera_ID_588;Benzeneacetamide, 3,4-dichloro-N-methyl-N-[(1R,2R)-2-(1-pyrrolidinyl)cyclohexyl]-, methanesulfonate (1:1);MLS000069740;trans-(+/-)-3,4-Dichloro-N-methyl-N-(2-[1-pyrrolidinyl]cyclohexyl)benzeneacetamide methanesulfonate;Lopac-D-8040;U-50488 methane sulfonate;HMS2232L15;2-(3,4-dichlorophenyl)-N-methyl-N-((1R,2R)-2-(pyrrolidin-1-yl)cyclohexyl)acetamide methanesulfonate;MLS001076340;83913-05-7;2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide;methanesulfonic acid;DTXSID301004058;(+/-)-trans-U-50488 methanesulfonate salt;83913-06-8;SMR000058892;Benzeneacetamide, 3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)-, trans-(+-)-, monomethanesulfonate;U50,488H;NCGC00016144-01;trans-(+/-)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide hydrochloride
SMILES:	ClC1=C(C=CC(=C1)CC(N(C)[C@@H]1CCCC[C@H]1N1CCCC1)=O)Cl.S(C)(=O)(=O)O
Formula:	C₂₀H₃₀Cl₂N₂O₄S
M.Wt:	465.43
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC65211	KT-474	KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.
DC79876	(±)-U-50488	(±)-U-50488 ((±)-trans-(1R,2R)-U-50488) is a selective kappa opioid receptor agonist. (±)-U-50488 can improve symptoms related to status epilepticus, but has no significant effect on spontaneous seizure episodes. (±)-U-50488 can be used for research of epilepsy.
DC74523	XY-07-35	XY-07-35 is a potent, selective HDAC6 proteolysis targeting chimera (PROTAC) degrader with IC50 of 48.5 nM.
DC74514	SelDeg51	SelDeg51 (Selective Degrader of FKBP51) is a potent, selective FKBP51 PROTAC with Kd of 18 nM, Emax=90%.
DC74496	HJM-561	HJM-561 is a potent, selective and orally bioavailable EGFR PROTAC degrader, selectively degrades the EGFR C797S-containing triple mutants Del19/T790M/C797S and L858R/T790M/C797S with DC50 values of 9.2 nM and 5.8 nM, respectively.
DC74494	GNE-0011	GNE-0011 is a monovalent, JQ1-based BRD4 degrader that is not linked to an E3 ligase binder, triggers proteasomal and ubiquitin-dependent selective degradation of BRD4 over BRD2 and BRD3.
DC72756	JQAD1	JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
DC46405	ARD-2128	ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
DC46309	Boc-piperazine-benzoic acid	Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128.
DC45754	ACBI1	ACBI1 is a potent and cooperative PROTAC degrader of SMARCA2, SMARCA4 and PBRM1 with DC50 of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 induces anti-proliferative effects and apoptosis.